CARVD-AHF
N
Nicholas Harrison
Primary Investigator
Enrolling By Invitation
18-100 years
All
Phase
N/A
150 participants needed
1 Location
Brief description of study
There is a critical need to develop effective treatments for central apnea during heart failure hospitalization. Lung ultrasound and molecular markers from blood tests may indicate patients needing alternate dosing regimens for decongestion, typically through diuresis, which in turn may be related to central apnea.
Detailed description of study
Objective 1: Identify reversible clinical predictors of dynamic change in polysomnographic central apnea burden during acute heart failure hospitalization.
Objective 2: Identify in-hospital disordered breathing mediators of cardiac dysfunction lasting after discharge.
Objective 3: Create a biospecimen repository of plasma and serum to be analyzed in future studies for novel molecular markers associated with central apnea and/or cardiac dysfunction.
Objective 2: Identify in-hospital disordered breathing mediators of cardiac dysfunction lasting after discharge.
Objective 3: Create a biospecimen repository of plasma and serum to be analyzed in future studies for novel molecular markers associated with central apnea and/or cardiac dysfunction.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: heart failure,apnea
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria:
- · ED patients ≥18 years old· The treating clinician suspects a diagnosis of AHF· Patient has sonographic diagnostic criteria for AHF (≥1 lung zone bilaterally with B-lines) by standard of care lung ultrasound exam· Lung ultrasound is performed prior to, or <3 hours after, the first IV dose of loop diuretic.
Exclusion Criteria:
- · Fixed/preexisting neurologic disease potentially causing central apnea (a. traumatic brain injury, b. disabling stroke)· Conditions other than cardiogenic pulmonary edema which may show bilateral B-lines on lung ultrasound (a. pulmonary fibrosis, b. bilateral pneumonias (including COVID-19), c. aspiration pneumonia, d. ARDS e. Sarcoidosis)
Updated on
01 Aug 2024.
Study ID: 11550, EMER-IIR-CARVD-AHF
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
